Foundayo (Orforglipron) Weight Loss Pill in the UAE: A Doctor-Led Guide
Dr. Hecham Harb
Consultant Endocrinologist & Medical Director
Book Your Consultation
- Specialist consultation
- Personalized Coaching
- Body Composition Analysis
01 Introduction
Foundayo (orforglipron) is the first once-daily oral GLP-1 receptor agonist approved by the Emirates Drug Establishment for chronic weight management. Developed by Eli Lilly, the company behind Mounjaro, it can be taken at any time of day, with or without food or water. In the ATTAIN-1 phase 3 trial, the average weight reduction at the highest dose was about 12.4% over 72 weeks, with a subset of participants achieving around 15%. At Endocare, Foundayo is prescribed by a specialist endocrinologist and combined with structured lifestyle coaching, which can meaningfully accelerate and improve long-term weight loss.
Key Takeaways
- Foundayo is the brand name for orforglipron, a small-molecule, non-peptide GLP-1 receptor agonist in tablet form.
- It is taken once daily, at any time, with no food or water restrictions.
- The Emirates Drug Establishment approved Foundayo for the UAE, with rollout beginning in May 2026.
- Eligibility is generally a BMI of 30 or above, or a BMI of 27 or above with a weight-related condition such as hypertension, dyslipidaemia, or type 2 diabetes.
- In clinical trials, average weight loss at the highest dose was 12.4% over 72 weeks.
- It is a prescription-only medicine that is not suitable for everyone.
- At Endocare, Foundayo is prescribed by a specialist endocrinologist and supported by ongoing lifestyle coaching.
Calculate your expected weight loss with Foundayo
Calculate your expected weight loss with Foundayo
current weight:
lose up to:
02 What Is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral medication developed by Eli Lilly for chronic weight management in adults. It belongs to the GLP-1 receptor agonist class, the same family of medicines that includes Mounjaro, Wegovy, and Ozempic, but with one important difference.
Foundayo is a small-molecule, non-peptide compound, which means it can be absorbed when taken as a tablet rather than needing to be injected.
The Emirates Drug Establishment approved Foundayo for use in the UAE, placing the country among the first in the world to register this oral therapy for obesity. Availability began rolling out from May 2026.
For many patients, the most practical feature of Foundayo is the format itself. The tablet can be swallowed at any time of the day, with or without food, and it does not need refrigeration. That removes some of the routine friction that has historically discouraged people from staying on injectable GLP-1 therapy long term. Foundayo joins a growing set of GLP-1 weight loss options in the UAE, alongside established injectable therapies.
03 How Does Foundayo Work for Weight Loss?
Foundayo activates the same GLP-1 receptors involved in appetite regulation and blood-sugar control. GLP-1 is a hormone your gut naturally produces after eating. It signals fullness to the brain, slows the rate at which the stomach empties, and supports steady blood-sugar levels.
When you take Foundayo, the medication binds to GLP-1 receptors in the brain and gut, which can help:
- Reduce overall hunger and the frequency of food cravings
- Increase the feeling of fullness after meals
- Slow gastric emptying, so meals leave you feeling satisfied for longer
- Support more stable blood-sugar levels throughout the day
What makes Foundayo different from older oral options is that it is a small-molecule compound rather than a peptide. Peptide-based GLP-1 medications such as semaglutide are broken down quickly in the digestive system, which is why they have traditionally been given as injections. The chemistry of orforglipron allows it to remain stable in tablet form and to be absorbed without specific food or water rules.
Foundayo is not a stimulant, a fat blocker, or a thyroid medication. It is a receptor agonist, meaning it works with hormonal signaling pathways your body already uses to manage energy and appetite. For patients with insulin resistance, GLP-1 therapy can also support more stable blood sugar over time. We explain this further in our guide on weight loss injections and insulin resistance.
04 Who Is Foundayo For?
Foundayo is intended for adults with obesity, or for adults with overweight who also have at least one weight-related medical condition. The general eligibility criteria used in the UAE are:
- A body mass index (BMI) of 30 or above, or
- A BMI of 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease
Foundayo is not approved for cosmetic weight loss and is not intended for short-term use. It is positioned as part of long-term chronic-weight-management care, similar in approach to other GLP-1 therapies.
In practice, Foundayo may be a particularly useful option for patients who:
- Are needle-averse or strongly prefer an oral medication
- Travel often and find injection routines difficult to maintain
- Have responded well to injectable GLP-1 therapy and want a maintenance option
- Cannot tolerate the higher doses of injectable medications
- Have specific lifestyle reasons that make weekly injections impractical
Suitability is decided during your specialist consultation, based on your medical history, current medications, blood tests, and overall goals. Foundayo is not the right choice for everyone, and your endocrinologist will help you compare it against injectable options in a clinical context. If you have read mixed information online, our overview of the most common myths about weight loss injections addresses many of the same questions that apply to oral GLP-1 therapy.
05 How Much Weight Can You Lose on Foundayo?
The most informative data on Foundayo comes from the ATTAIN-1 phase 3 trial, a 72-week study of adults with obesity or overweight with weight-related comorbidities, without type 2 diabetes. The trial was published in The New England Journal of Medicine.
Key findings from ATTAIN-1:
- Participants on the highest dose lost an average of 27.3 lbs, or about 12.4% of their starting body weight, over 72 weeks
- 6% of participants on the highest dose achieved at least 10% weight loss
- A subset of participants on the highest dose reached around 15% weight loss
- Improvements were seen in cardiometabolic markers including cholesterol, waist circumference, and blood pressure
Two important notes on these numbers. First, these are averages from a large clinical trial. Individual results vary, sometimes considerably, based on baseline weight, adherence, dose tolerance, and how well lifestyle changes are integrated. Second, this level of weight loss is meaningful, but on average it is lower than what has been reported for injectable tirzepatide (Mounjaro) and somewhat lower than for semaglutide (Wegovy). Foundayo’s appeal is not maximum weight loss. It is the combination of meaningful weight loss with the convenience of an oral pill.
It is also worth noting that the trial results reflect medication alone, with limited lifestyle support. In real-world practice, combining Foundayo with structured nutrition, activity, sleep, and stress coaching tends to accelerate weight loss and improve long-term maintenance, because it addresses the underlying drivers that medication alone cannot reach.
There is also early evidence from the ATTAIN-MAINTAIN study suggesting that patients who reached a plateau on Wegovy or Zepbound and then switched to orforglipron were able to maintain most of the weight they had already lost. This positions Foundayo as a useful maintenance option, not only as a starting therapy. Patients who have previously used Zepbound or other tirzepatide-based therapy may also consider Foundayo as an oral option once their specialist confirms it is appropriate.
06 Foundayo Dosing and Titration Schedule
Foundayo is started at a low dose and gradually increased to give your body time to adapt. This step-by-step approach helps reduce gastrointestinal side effects, which are most common in the first weeks of treatment or after a dose change.
The general dosing approach is:
- Starting dose: 8 mg once daily, taken at the same time each day if possible
- First step up: After at least 30 days, the dose may be increased to the next level (commonly 2.5 mg)
- Continued titration: Further increases happen at intervals of at least 30 days, moving up through 5.5 mg, 9 mg, and 12 mg as tolerated
- Maintenance dose: The maintenance dose is decided by your specialist based on how you tolerate the medication and the response you are seeing
The tablet should be swallowed whole, not crushed, broken, or chewed. If you miss a dose, take it as soon as you remember the same day. Do not take two tablets on the same day to make up for a missed dose.
Your specialist will set your titration schedule. The pace is individual, and there is rarely a benefit to moving up doses faster than your body is ready for.
07 Possible Side Effects of Foundayo
The side-effect profile of Foundayo is broadly consistent with the wider GLP-1 receptor agonist class. Most side effects are gastrointestinal, are mild to moderate, and tend to settle as your body adjusts to the medication or after a dose stays steady for a few weeks.
The most commonly reported side effects include:
- Nausea
- Constipation
- Diarrhoea
- Vomiting
- Indigestion
- Abdominal pain or bloating
- Headache
- Fatigue
- Belching, heartburn, or gas
- Hair shedding in some patients
In ATTAIN-1, treatment discontinuation due to adverse events was generally in line with other GLP-1 medications. Most people who experience side effects manage them with small adjustments to eating patterns, hydration, and pacing of dose changes.
A few practical points worth knowing:
- Eating slowly, in smaller portions, and avoiding very fatty or very sugary meals reduces nausea for many patients
- Adequate water intake helps with constipation, which is one of the more common issues
- Hair shedding linked to GLP-1 therapy is most often related to rapid weight loss and nutritional gaps, especially in protein, iron, vitamin B12, zinc, and biotin
- Significant or worsening abdominal pain, persistent vomiting, signs of dehydration, or symptoms suggesting pancreatitis should be reported to your doctor without delay
Side effects feel different on each person. If something is not settling, your endocrinologist may slow the dose increase or hold the current dose for longer rather than push forward. Patients often ask whether starting any GLP-1 therapy is safe in the long term. The short answer is that medical weight loss is generally safe when delivered with proper supervision, regular labs, and ongoing follow-up.
08 Who Should Not Take Foundayo
Foundayo is not appropriate for everyone. It should not be used by people who:
- Have a personal or family history of medullary thyroid carcinoma
- Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Have a known allergy or hypersensitivity to orforglipron or any of the components of the tablet
- Are pregnant, planning pregnancy in the near future, or breastfeeding
- Are already using another GLP-1 receptor agonist (combining them is not recommended)
Caution is also advised in patients with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease such as gastroparesis, or significant kidney disease. Your specialist will review your full medical history before prescribing.
Foundayo is also not approved for use in children. Safety and efficacy in patients under 18 have not been established.
09 Foundayo vs Injectable GLP-1 Medications
A reasonable question for many patients is whether to choose Foundayo or one of the established injectable options, and how doctors typically compare Mounjaro, Ozempic, and Wegovy. There is no single answer that applies to everyone. The right choice depends on your medical history, your goals, your tolerance, and your lifestyle.
| Feature | Foundayo (orforglipron) | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|---|
| Format | Oral tablet | Weekly injection | Weekly injection |
| Class | Oral GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Frequency | Once daily | Once weekly | Once weekly |
| Food and water restrictions | None | None | None |
| Refrigeration | Not required | Required before first use | Required before first use |
| Average weight loss highest dose, longest trial | About 12.4% over 72 weeks | About 20 to 22% over 72 weeks | About 15% over 68 weeks |
| UAE approval | Yes | Yes | Yes |
10 Foundayo vs Mounjaro (Tirzepatide)
Mounjaro, the brand name for tirzepatide, activates two receptors, GIP and GLP-1, which is part of why it has produced the highest average weight loss in head-to-head trials so far. In SURMOUNT-5, tirzepatide outperformed semaglutide. Compared with Foundayo’s 12.4% average at 72 weeks, tirzepatide’s averages are higher.
That does not automatically make Mounjaro the right choice. Some patients cannot tolerate the higher doses, find weekly injections difficult to maintain, or prefer the simplicity of a daily tablet. Foundayo gives a useful alternative for those situations.
11 Foundayo vs Wegovy and Ozempic (Semaglutide)
Wegovy and Ozempic both contain semaglutide, a GLP-1 medication available in the UAE. Wegovy is approved for chronic weight management, while Ozempic is approved for type 2 diabetes. In the UAE, Ozempic is prescribed for weight loss only when the patient has diabetes or prediabetes.
Compared with semaglutide-based injections, Foundayo offers a similar mechanism, slightly lower average weight loss in trials, and the meaningful practical benefit of oral dosing. If you have done well on semaglutide and are looking to simplify your routine or move into a maintenance phase, Foundayo can be considered.
If you are weighing oral options more broadly, it can help to understand how the Wegovy pill compares as well.
The choice between weight loss injections and weight loss pills is not just about efficacy. It is about what you can realistically commit to, comfortably, for the long term.
12 Foundayo Availability and Cost in the UAE
Foundayo became available across UAE pharmacies from May 2026, following approval by the Emirates Drug Establishment. It is a prescription-only medicine. You cannot buy it over the counter, and you should not source it from unverified online channels.
Foundayo pricing in the UAE is standardised across pharmacies. Current prices per dose are:
- Foundayo 0.8 mg: 773 AED
- Foundayo 2.5 mg: 773 AED
- Foundayo 5.5 mg: 1,115 AED
- Foundayo 9.0 mg: 1,412 AED
- Foundayo 14.5 mg: 1,599 AED
- Foundayo 17.2 mg: 1,599 AED
A note on insurance: GLP-1 medications in the UAE are typically reimbursed only when prescribed for diabetes or prediabetes. For weight loss without a qualifying diagnosis, Foundayo is generally self-pay. Endocare provides the medical report and invoice you need to submit a claim, but final approval rests with your insurer.
13 How Endocare Prescribes Foundayo
Endocare’s approach to Foundayo follows the same medically supervised model used for other GLP-1 therapies. The aim is not just to start a medication, but to use it well, manage side effects properly, and protect long-term results.
Initial Specialist Consultation
Your first visit is with a consultant endocrinologist. Treatment decisions and follow-up are managed by our endocrinology care team, including consultant endocrinologists and clinical health coaches. The conversation covers your weight history, medical conditions, current medications, family history, lifestyle, and goals. This is where we decide whether Foundayo is appropriate for you, or whether another option suits you better.
Body Composition and Lab Review
Before starting any GLP-1 medication, we review a recent blood test (within the last three months) or arrange an at-home blood draw. We also do a body-composition analysis, which gives us your body-fat percentage, visceral-fat rating, skeletal-muscle mass, and hydration status. These numbers matter, because the goal is to reduce body fat while protecting muscle, not simply to drop a number on the scale.
Ongoing Follow-Up and Lifestyle Coaching
Patients are seen monthly to review progress, adjust the dose if needed, and check tolerability. Lifestyle coaching runs alongside the medication and focuses on four areas: nutrition, physical activity, sleep, and stress.
Lifestyle coaching is not a nice-to-have. In our clinical experience, patients who combine Foundayo with structured coaching tend to lose more weight than what the medication trials alone suggest, and they are far more likely to keep the weight off once the dose is tapered. The reason is simple: medication can suppress appetite and ease food noise, but it cannot rebuild eating patterns, protect muscle mass, improve sleep, or address the stress and emotional drivers that often sit underneath weight gain. Coaching addresses those root causes, which is what turns short-term loss into long-term results.
Medication delivery is free for all Endocare patients, with same-day delivery in Dubai and within 48 hours across the UAE.
14 FAQ
What is Foundayo and who makes it?
Foundayo is the brand name of orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly for chronic weight management.
How is Foundayo different from Ozempic, Mounjaro, and Wegovy?
Ozempic and Wegovy contain semaglutide, given as weekly injections. Mounjaro contains tirzepatide, also a weekly injection, but it works on two receptors (GIP and GLP-1). Foundayo is taken once daily as a tablet and works on the GLP-1 receptor alone. Injectables generally produce higher average weight loss in trials. Foundayo offers a meaningful but slightly lower average weight loss with the convenience of an oral pill.
How much weight can I lose on Foundayo?
In the ATTAIN-1 trial, patients on the highest dose lost an average of 12.4% of their starting body weight over 72 weeks. Individual results vary depending on dose tolerance, adherence, lifestyle changes, and baseline health.
What are the most common side effects of Foundayo?
The most commonly reported side effects are gastrointestinal, including nausea, constipation, diarrhoea, vomiting, abdominal pain, and indigestion. Headache, fatigue, and hair shedding are also reported. Most side effects are mild to moderate and improve as your body adjusts.
Can I take Foundayo if I have type 2 diabetes?
Orforglipron has been studied in adults with type 2 diabetes through the ATTAIN-2 trial, published in The Lancet. In the UAE, Foundayo’s approved use is for chronic weight management. If you have type 2 diabetes, your specialist will decide whether Foundayo is appropriate alongside your current diabetes care, or whether a different GLP-1 medication suits you better.
Can I switch from Mounjaro or Wegovy to Foundayo?
Switching from an injectable GLP-1 to Foundayo is possible, but it should only be done under the guidance of your specialist to ensure a safe transition. Your doctor will plan the timing based on your last injection, your current dose, your response so far, and your overall medical picture. Do not stop or change a GLP-1 medication on your own.
How do I start Foundayo at Endocare?
You book an initial consultation with one of our endocrinologists. We review your medical history and labs, perform a body-composition analysis, and decide together whether Foundayo is suitable. If it is, we prescribe the starting dose and arrange delivery.
When will Foundayo be available across the UAE?
Foundayo became available in the UAE from May 2026 following Emirates Drug Establishment approval.
Does insurance in the UAE cover Foundayo?
Most UAE insurers reimburse GLP-1 medications only when prescribed for diabetes or prediabetes. For weight loss without a qualifying diagnosis, Foundayo is typically self-pay. Endocare provides the documents you need to submit a claim, but the final decision rests with your insurer.
Speak to an Endocare Specialist About Foundayo
If you are considering Foundayo and want a clear, medically grounded view of whether it fits your situation, book a consultation with one of our endocrinologists. We will review your history, run the right tests, compare your options honestly, and help you build a plan you can actually follow.
You can also review our medical weight loss package pricing before your visit.
Book Your Consultation
- Specialist consultation
- Personalized Coaching
- Body Composition Analysis